Evidence map›Paper›PMID 40671773›Full record

ArticleGland surgery2025

Individualized survival prediction and risk stratification using machine learning for patients with malignant struma ovarii: a population-based study with external validation.

Shangcheng Yan, Zhen Cao, Qiyao Zhang, Bingrong Chen, Hao Wu, Hongtao Cao, Xiaobin Li, Yaqi Wang, Yalei Wang, Yonghui Chen and 1 more

Abstract read
In one paragraph

Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shangcheng Yan *Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0002-6008-722X
Zhen Cao *Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qiyao ZhangDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bingrong ChenDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hao WuDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hongtao CaoDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaobin LiDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yaqi WangDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yalei WangDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yonghui ChenDepartment of Nuclear Medicine and Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ziwen LiuDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Malignant struma ovarii (MSO) is a rare thyroid-type cancer originating in ovarian teratoma. Prognosis of MSO is less studied without unanimous staging or stratification system. This study aimed to developed and validated a machine learning (ML)-based model to predict overall survival (OS) for patients with MSO and to risk-stratify them. Methods: Patients with histologically confirmed MSO diagnosed in 1975-2021 from the Surveillance, Epidemiology, and End Results (SEER) program were identified as the training cohort. Patients in a systematic literature review were collected as the testing cohort. OS was selected as the outcome, while demographic, clinicopathological and therapeutic information were used as features. Following data encoding, imputing and scaling, univariate feature selection was performed. Cox proportional hazard (CoxPH), Cox with elastic net penalty (CoxNet), random survival forest (RSF), gradient boosting machine (GBM), and survival tree (ST) models were trained and tuned. Each model was evaluated on its c-index, time-dependent area under the curve (AUC), time-dependent Brier score (BS) and stratification ability in the training and the testing cohort respectively. The algorithm that performed the best in the testing cohort was finally chosen for SHapley Additive exPlanations (SHAP) interpretation and Streamlit web application deployment. Results: The study included 120 and 194 patients in the training and testing cohort respectively. At the end of follow-up (median time 115.5 and 32.5 months respectively), 101 (84.2%) and 181 patients (93.3%) survived respectively. RSF had the best performance in the testing cohort, possessing the highest c-index (0.841, 95% confidence interval: 0.732-0.916), the highest mean AUC (0.852), the lowest integrated BS (0.042), and the smallest P value (<0.001) on log-rank test comparing the stratified groups. According to SHAP, older age, hysterectomy, larger tumor size and more advanced American Joint Committee on Cancer stage had the strongest predictive power for worse OS among all 13 features. An interactive application (https://mso-surv.streamlit.app/) was then implemented which can display the predicted Kaplan-Meier curve, survival probability, risk stratification and the contributions of features for the output. Conclusions: We reported the first externally tested time-to-event prognostic prediction model for MSO. ML algorithms enabled precise individual-patient prediction and stratification, and can potentially assist patient counselling and decision-making for treatment and surveillance.

Indexed as

machine learning (ML)Malignant struma ovarii (MSO)prediction modelrisk stratificationsurvival analysis

Identifiers

PMID40671773
PMCPMC12261249

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.